Better Therapeutics, Inc. BTTX
0.00
0.00
NaN
as of 25 Sep
- Market cap
- $850.0K
- P/E
- 0.0×
Follow BTTX
| Sep '23 | Jun '23 | Mar '23 | Dec '22 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
0.57 | 0.54 | 0.62 | 1.37 |
+8 more quarters Free account |
Net Debt/EBITDA |
(1.71) | (1.29) | (1.04) | 0.11 | |
Debt/Assets |
133.44% | 122.48% | 113.52% | 64.86% | |
Debt/Equity |
(1.44) | (1.32) | (1.48) | (16.55) | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
1.01 | 0.67 | 0.93 | 0.72 | |
Capex/Depreciation |
0.08 | (0.63) | (0.69) | (0.50) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.15) | (0.18) | (0.39) | (0.28) | |
Cash per Share |
0.17 | 0.20 | 0.25 | 0.67 | |
Shareholders Equity per Share |
(0.26) | (0.35) | (0.41) | (0.04) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.26) | (0.35) | (0.41) | (0.04) | |
Free Cash Flow |
(5.88) | (5.59) | (9.24) | (6.70) | |
Working Capital |
(5.59) | (6.45) | (5.20) | 4.95 | |
Capital Expenditures |
0.07 | (0.50) | (0.52) | (0.36) | |
Net Current Asset Value |
(13.31) | (14.97) | (14.20) | (5.40) | |
| Other line items | |||||
Quick Ratio |
0.51 | 0.45 | 0.44 | 1.17 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.15) | (0.16) | (0.37) | (0.27) | |
Capex per Share |
0.00 | (0.02) | (0.02) | (0.02) | |
Average Payables |
1.78 | 2.04 | 1.62 | 2.28 | |
Average Assets |
19.47 | 24.35 | 26.55 | 36.95 | |
Average Common Equity |
(1.34) | 3.63 | 8.80 | 17.91 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates